Ang2-Targeted Combination Therapy for Cancer Treatment

Abstract

Angiopoietin-2 (Ang2), a member of the angiopoietin family, is widely involved in the process of vascular physiology, bone physiology, adipose tissue physiology and the occurrence and development of inflammation, cardiac hypertrophy, rheumatoid, tumor and other diseases under pathological conditions. Proliferation and metastasis of cancer largely depend on angiogenesis. Therefore, anti-angiogenesis has become the target of tumor therapy. Due to the Ang2 plays a key role in promoting angiogenesis and stability in vascular physiology, the imbalance of its expression is an important condition for the occurrence and development of cancer. It has been proved that blocking Ang2 can inhibit the growth, invasion and metastasis of cancer cells. In recent years, research has been constantly supplemented. We focus on the mechanisms that regulate the expression of Ang2 mRNA and protein levels in different cancers, contributing to a better understanding of how Ang2 exerts different effects in different cancers and stages, as well as facilitating more specific targeting of relevant molecules in cancer therapy. At the same time, the importance of Ang2 in cancer growth, metastasis, prognosis and combination therapy is pointed out. And finally, we will discuss the current investigations and future challenges of combining Ang2 inhibition with chemotherapy, immunotherapy, and radiotherapy to increase its efficacy in cancer patients. This review provides a theoretical reference for the development of new targets and effective combination therapy strategies for cancer treatment in the future.

Identification of the hub genes associated with prostate cancer tumorigenesis

“…Ang-II can lead to disconnection between endothelial cells and surrounding cells, resulting in vascular instability and endothelial activation (31). VEGF cooperates with Ang-II to induce endothelial cells to receive the budding signal of VEGF and other angiogenesis inducers (32). Neovascularization occurs continuously in tumor tissues and promotes the development of tumor cells.…”

Targeting vascular normalization: a promising strategy to improve immune–vascular crosstalk in cancer immunotherapy

“…The physiologic balance between anti-angiogenic and proangiogenic factors is disrupted in the tumor tissues. High concentrations of pro-angiogenic factors, such as VEGF, angiopoietin 2 (ANG2), and platelet-derived growth factor (PDGF), are present in the TME (15) of various cancers, such as non-small cell lung cancer, gastric cancer, colorectal cancer, and glioma (16)(17)(18)(19)(20). In addition, hypoxia is responsible for tumor angiogenesis.…”

DCE-MRI-based radiomics in predicting angiopoietin-2 expression in hepatocellular carcinoma

“…Tumor angiogenesis is the result of the complex interaction among various proangiogenic mediators and effector cells [ 2 ]. The rapid deepening of the understanding of the molecular mechanisms of angiogenesis has led to the emergence of antiangiogenic drugs to treat cancer, with thousands of patients benefitting from vascular endothelial growth factor (VEGF) and angiopoietin inhibitors [ 3 , 4 ]. Angiopoietins are ligands for the endothelial cell receptor Tie-2 and play an important role in tumor angiogenesis.…”